Effect of remimazolam on the incidence of delirium after transcatheter aortic valve implantation under general anesthesia: a retrospective exploratory study
Journal of Anesthesia · 2023-04 · 37 (2) · 210-218
DOI: 10.1007/s00540-022-03148-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Anesthesia, online erschienen am 04.12.2022. Verfasst von Shohei Kaneko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Emergence Delirium, Aortic Valve Stenosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Themen: Delir
Abstract (Originalsprache)
PURPOSE: Delirium after transcatheter aortic valve implantation (TAVI) should be prevented because it is associated with worse patient outcomes. Perioperative administration of benzodiazepines is a risk factor for postoperative delirium; however, the association between remimazolam, a newer ultrashort-acting benzodiazepine for general anesthesia, and postoperative delirium remains unclear. This study aimed to evaluate whether remimazolam administration during TAVI under general anesthesia affected the incidence of postoperative delirium. METHODS: This single-center retrospective study recruited all adult patients who underwent transfemoral TAVI (TF-TAVI) under general anesthesia between March 2020 and May 2022. Patients were divided into the remimazolam (R) and propofol (P) groups according to the sedative used for anesthesia. In the R group, all patients received flumazenil after surgery. The primary endpoint was the incidence of delirium within 3 days after surgery. Factors associated with delirium after TF-TAVI were examined by multiple logistic regression analysis. RESULTS: Ninety-eight patients were included in the final analysis (R group, n = 40; P group, n = 58). The incidence of postoperative delirium was significantly lower in the R group than in the P group (8% vs. 26%, p = 0.032). Multiple logistic regression analysis revealed that remimazolam (odds ratio 0.17, 95% CI 0.04-0.80, p = 0.024) was independently associated with the incidence of postoperative delirium, even after adjustment for age, sex, preoperative cognitive function, history of stroke, and TF-TAVI approach. CONCLUSION: Remimazolam may benefit TF-TAVI in terms of postoperative delirium; however, its usefulness must be further evaluated in extensive prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Care Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. s-kaneko@nagasaki-u.ac.jp.
- Department of Anesthesiology and Intensive Care Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Zitieren
APA
Kaneko, S., Morimoto, T., Ichinomiya, T., Murata, H., Yoshitomi, O., & Hara, T. (2023). Effect of remimazolam on the incidence of delirium after transcatheter aortic valve implantation under general anesthesia: a retrospective exploratory study. Journal of Anesthesia, 37(2), 210-218. https://doi.org/10.1007/s00540-022-03148-2
Vancouver
Kaneko S, Morimoto T, Ichinomiya T, Murata H, Yoshitomi O, Hara T. Effect of remimazolam on the incidence of delirium after transcatheter aortic valve implantation under general anesthesia: a retrospective exploratory study. Journal of Anesthesia. 2023;37(2):210-218. doi:10.1007/s00540-022-03148-2
BibTeX
@article{Kaneko2023,
author = {Kaneko, Shohei and Morimoto, Takayuki and Ichinomiya, Taiga and Murata, Hiroaki and Yoshitomi, Osamu and Hara, Tetsuya},
title = {Effect of remimazolam on the incidence of delirium after transcatheter aortic valve implantation under general anesthesia: a retrospective exploratory study},
journal = {Journal of Anesthesia},
year = {2023},
volume = {37},
number = {2},
pages = {210--218},
doi = {10.1007/s00540-022-03148-2}
}
EUVIMED